Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Jingsheng Hua"'
Autor:
Xiebing Bao, Jingyun Chi, Yiwei Zhu, Minfeng Yang, Jiahui Du, Zaixiang Tang, Xiaogang Xu, Genxiang Mao, Zhibing Wu, Jun Chen, Jingsheng Hua, Ting Xu, Song-Bai Liu
Publikováno v:
Cancer Cell International, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background As a core member of the FA complex, in the Fanconi anemia pathway, FAAP24 plays an important role in DNA damage repair. However, the association between FAAP24 and patient prognosis in AML and immune infiltration remains unclear.
Externí odkaz:
https://doaj.org/article/5fa7de4e438d43f3b5f18cb2c7e1ea8c
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundAcute myeloid leukemia (AML) is an aggressive hematopoietic malignancy. Transient receptor potential (TRP) channels in AML still need to be further explored. A TRP channel-related model based on machine learning was established in this stud
Externí odkaz:
https://doaj.org/article/a9ed67532b124e8c904c183436638ced
Autor:
Xiebing Bao, Yao Chen, Xiao Lou, Jiahui Du, Huijun Li, Nian Liu, Zaixiang Tang, Jingsheng Hua, Weiqiang Guo, Song-Bai Liu
Publikováno v:
Clinical and Translational Oncology. 25:1053-1066
Acute myeloid leukemia (AML) is a hematological malignancy with high molecular and clinical heterogeneity, and is the most common type of acute leukemia in adults. Due to limited treatment options, AML is prone to relapse and has a poor prognosis. Ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13ad401f805f32aaa06517628c2b99d7
https://doi.org/10.1007/s12094-022-03012-5
https://doi.org/10.1007/s12094-022-03012-5
Autor:
Xiebing Bao, Lili Zhou, Miao Miao, Yue Han, Weiqing Qian, Huiying Qiu, Jingsheng Hua, Jian Zhang, Caixia Li, Zhengzheng Fu, Depei Wu, Xiaoxia Wu
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:610-616
Introduction Currently, effective and safe salvage therapies are limited among patients with relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Anti-CD19 chimeric antigen receptor T (CAR T) cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a682bc9e3d2d1e0a531650d479e73e60
https://doi.org/10.1016/j.clml.2020.04.007
https://doi.org/10.1016/j.clml.2020.04.007
Autor:
Weiqing Qian, Jian Zhang, Lei Yu, Lili Zhou, Huiying Qiu, Suning Chen, Xiaoxia Wu, Jingsheng Hua
Publikováno v:
OncoTargets and therapy
Pediatric Philadelphia chromosome-like (Ph-like) acute B-lymphoblastic leukemia (B-ALL), a high-risk subset of B-ALL characterized by a gene expression profile similar to that of Ph-positive ALL, has extremely poor outcome after a relapse following
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7d44a9361dc06996eb4955206429416
http://europepmc.org/articles/PMC7098167
http://europepmc.org/articles/PMC7098167
Autor:
Jiexian Ma, Xiaohua Wang, Zhaoling Zou, Mixue Xie, Jingsheng Hua, Youdao Liang, Min Wu, Ruyu Yang, Yingwei Hu, Yu Xu, Yanhui Xie, Xiujin Ye, Xiaoqin Wang
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(10)
Background Decitabine are used in the treatment of myelodysplastic syndrome (MDS), but none trials reported overall survival improvement. Methods High-risk MDS and MDS transformed AML (sAML) patients (IPSS-R > 4.5, age above 60 years) in 6 medical ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84253ebb600030d9d1d7059ca16579a
https://pubmed.ncbi.nlm.nih.gov/34226168
https://pubmed.ncbi.nlm.nih.gov/34226168
Autor:
Miao Miao, Huiying Qiu, Chengcheng Fu, Xiebing Bao, Depei Wu, Suning Chen, Xiaoxia Wu, Jingsheng Hua, Yue Han, Xinyou Zhang, Jian Zhang, Xiaowen Tang, Lili Zhou, Caixia Li
Publikováno v:
Bone marrow transplantation. 56(5)
The efficacy and safety of donor-derived anti-CD19 CAR T cells vs DLI for the management of relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allo-hematopoietic stem cell transplantation (HSCT) remain unclear. Thirteen B-ALL patients with re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc63409b45d58b96156c9f86be203c45
https://pubmed.ncbi.nlm.nih.gov/33235353
https://pubmed.ncbi.nlm.nih.gov/33235353
Autor:
Jingsheng Hua, Weiqing Qian, Xiaoxia Wu, Lili Zhou, Lei Yu, Suning Chen, Jian Zhang, Huiying Qiu
Publikováno v:
OncoTargets and therapy
Hua J, Qian W, Wu X, et al. Onco Targets Ther. 2020;13:2311– 2317. The authors of this paper have advised that the author and affiliation list on page 2311 is incorrect. The correct author and affiliation list is as follows:Jingsheng Hua 1,2,*Weiqi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64c92a73c9b5444d6d09bcf32da8ee23
http://europepmc.org/articles/PMC7156262
http://europepmc.org/articles/PMC7156262
Autor:
Shunrong Sun, Yanhui Xie, Hehe Sheng, Yingwei Hu, Jiexian Ma, Zhaolin Zhou, Min Wu, Mixue Xie, Jingsheng Hua, Ruyu Yang, Xiaohua Wang, Xiaoqin Wang, Xiujin Ye
Publikováno v:
SSRN Electronic Journal.
There is still a lack of effective treatments for elderly AML/MDS patients, especially those with TP53 mutation. We conducted a prospective, multicenter clinical trial to evaluate decitabine and etoposide based regimen in elderly AML/MDS patients and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4673fe4b8b7aebc76e87e99074d734e
https://doi.org/10.2139/ssrn.3707242
https://doi.org/10.2139/ssrn.3707242
Publikováno v:
OncoTargets & Therapy. Oct2016, Vol. 9, p6573-6579. 7p.